BLLN
BillionToOne, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$103.78
+2.72%Oct 14, 2026, 12:05 UTC
BillionToOne, Inc. announced that it plans to release financial results for the third quarter ended September 30, 2026, after market close on November 4, 2026, and hold a conference call that day.
Source:Sep 1, 2026, 13:00 UTC
BillionToOne launched Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, and expanded its Northstar Select panel from 84 to 102 genes.
Source:Aug 5, 2026, 23:05 UTC
Billiontoone reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses, and posted positive operating income and free cash flow.